5 active not recruiting, 2 withdrawn, 1 completed, 1 terminated. 10 Phase 2, 4 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 10 | Active not recruiting 5, Withdrawn 2, Completed 1, Terminated 1, Unknown 1 |
| Phase 1 | 4 | Active not recruiting 4 |
Follow Metastatic Rectal Adenocarcinoma: new trials by email Literature Review of Metastatic Rectal Adenocarcinoma trials Research Report on Metastatic Rectal Adenocarcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Botensilimab, Balstilimab and Regorafenib or Botensilimab and Balstilimab for the Treatment of Advanced or Metastatic Microsatellite Stable Colorectal Cancer Balstilimab, Biopsy, Biospecimen Collection - Advanced Colon Adenocarcinoma, Advanced Colorectal Adenocarcinoma | Phase 2 | Withdrawn | City of Hope Medical Center | 2024-11-01 | 2024-11-21 | |
| Tucatinib Combined with Trastuzumab and TAS-102 for the Treatment of HER2 Positive Metastatic Colorectal Cancer in Molecularly Selected Patients, 3T Study Trastuzumab, Trifluridine and Tipiracil Hydrochloride, Tucatinib - Metastatic Colon Adenocarcinoma, Metastatic Colorectal Adenocarcinoma | Phase 2 | Withdrawn | Academic and Community Cancer Research United | 2023-10-31 | 2024-09-19 | |
| FOLFOX and Bevacizumab in Combination With Botensilimab and Balstilimab (3B-FOLFOX) for the Treatment of Microsatellite Stable (MSS) Metastatic Colorectal Cancer Balstilimab, Bevacizumab, Biospecimen Collection - Metastatic Colon Adenocarcinoma, Metastatic Colorectal Adenocarcinoma | Phase 1 / Phase 2 | Active not recruiting | City of Hope Medical Center | 20 | 2023-05-03 | 2026-09-01 |
| Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF Mutation Cetuximab, Encorafenib, Nivolumab - Metastatic Colon Adenocarcinoma, Metastatic Rectal Adenocarcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 86 | 2022-07-19 | 2026-07-08 |
| LY3214996 and Cetuximab Alone or in Combination With Abemaciclib for the Treatment of Unresectable or Metastatic Colorectal Cancer Abemaciclib, Cetuximab, ERK1/2 Inhibitor LY3214996 - Metastatic Colon Adenocarcinoma, Metastatic Colorectal Carcinoma | Phase 1 / Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 46 | 2020-12-02 | 2026-10-05 |
| SX-682 and Nivolumab for the Treatment of RAS-Mutated, MSS Unresectable or Metastatic Colorectal Cancer, the STOPTRAFFIC-1 Trial CXCR1/2 Inhibitor SX-682, Nivolumab - Metastatic Colon Adenocarcinoma, Metastatic Colorectal Carcinoma | Phase 1 / Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 51 | 2020-10-14 | 2026-07-20 |
| Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer Panitumumab, Quality-of-Life Assessment, Questionnaire Administration - Metastatic Colon Adenocarcinoma, Metastatic Colorectal Carcinoma | Phase 2 | Unknown | Academic and Community Cancer Research United | 12 | 2020-04-24 | 2024-05-21 |
| TAS-102, Irinotecan, and Bevacizumab for the Treatment of Pre-treated Metastatic or Unresectable Colorectal Cancer, the TABAsCO Study Irinotecan, Bevacizumab, Trifluridine and Tipiracil Hydrochloride - Advanced Colorectal Carcinoma, Metastatic Colon Adenocarcinoma | Phase 2 | Completed | Roswell Park Cancer Institute | 42 | 2019-12-27 | 2026-02-10 |
| Savolitinib in Treating Patients With MET Amplified Metastatic or Unresectable Colorectal Cancer Savolitinib - Colorectal Carcinoma, Metastatic Colon Adenocarcinoma | Phase 2 | Terminated | National Cancer Institute (NCI) | 5 | 2019-07-25 | 2023-10-17 |
| Encorafenib, Cetuximab, and Nivolumab in Treating Patients With Microsatellite Stable, BRAFV600E Mutated Unresectable or Metastatic Colorectal Cancer Cetuximab, Encorafenib, Nivolumab - BRAF NP_004324.2:p.V600E, Metastatic Colon Adenocarcinoma | Phase 1 / Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 38 | 2019-06-14 | 2026-06-11 |
Colonic Neoplasms (10) · Rectal Neoplasms (10) · Colorectal Neoplasms (9) · Disease Progression (1)
Colonic Diseases (10) · Digestive System Diseases (10) · Digestive System Neoplasms (10) · Gastrointestinal Diseases (10) · Gastrointestinal Neoplasms (10) · Intestinal Diseases (10) · Intestinal Neoplasms (10) · Neoplasms (10) · Neoplasms by Site (10) · Rectal Diseases (10) · Colorectal Neoplasms (1) · Disease Attributes (1) · Pathologic Processes (1) · Pathological Conditions, Signs and Symptoms (1)
Cetuximab (3) · Nivolumab (3) · Trifluridine (3) · trifluridine tipiracil drug combination (3) · Bevacizumab (2) · Disulfides (2) · Magnetic Resonance Spectroscopy (2) · Specimen Handling (2) · balstilimab (2) · encorafenib (2) · regorafenib (2) · (225)Ac-DOTA-c(RGDyK) (1) · 1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine (1) · Biopsy (1) · Fluorouracil (1)
M.D. Anderson Cancer Center (3) · Academic and Community Cancer Research United (2) · City of Hope Medical Center (2) · National Cancer Institute (NCI) (2) · Roswell Park Cancer Institute (1)
United States (9) · Puerto Rico (1)
John H Strickler (3) · Marwan G Fakih (2) · Van K Morris (2) · Alisha Bent, MD (1) · Christine M Parseghian, MD (1) · Christos Fountzilas, MD (1)
P30CA015083 (2), P30CA033572 (2), R01CA187238 (1), U10CA180888 (1), UM1CA186704 (1)